Cash, cash equivalents and financial instruments amounting to €270 million ; US$5 million milestone payment received from Bristol-Myers Squibb for the initiation of a new Phase II trial in hemato...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) announced that it has received a US$5 million milestone payment from Bristol-Myers Squibb as part of the lirilumab licencing...

Third trial opened in the Phase II clinical program of IPH2201 - program rollout on track Trial conducted in the United States with leading investigator at OSU Innate Pharma SA (the “Company” -...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announced that the first patient was treated in the Phase I/II trial testing IPH2201, a first-in-class NKG2A checkpoint...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) announces that Professor Martine Bagot, Head of the Dermatology Department at the Saint-Louis Hospital in Paris and co-discoverer...

Landmark co-development and commercialization agreement with AstraZeneca for IPH2201 in immuno-oncology Cash and cash equivalents amounting to €279 million following initial payment of $250 million...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announced that the Data and Safety Monitoring Board (“DSMB”) completed its fifth assessment of the EffiKIR study and...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announced that Professor Martine Bagot, Head of the Dermatology Department at the Saint-Louis Hospital in Paris and co...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class therapeutic antibodies for cancer and inflammatory diseases, today...

Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) today announced that the co-development and commercialization agreement with AstraZeneca on Innate Pharma’s proprietary anti-NKG2A antibody...